Surgical indication of pulmonary metastasis arising from osteosarcoma or soft tissue sarcoma

Author(s):  
Akiisa Omura ◽  
Toru Kimura ◽  
Ryo Tanaka ◽  
Takashi Hiroshima ◽  
Tomohiro Maniwa ◽  
...  
2018 ◽  
Vol 38 (6) ◽  
pp. 3635-3639 ◽  
Author(s):  
TOMOHITO HAGI ◽  
TOMOKI NAKAMURA ◽  
YUICHI SUGINO ◽  
TAKAO MATSUBARA ◽  
KUNIHIRO ASANUMA ◽  
...  

2014 ◽  
Vol 53 (9) ◽  
pp. 1180-1187 ◽  
Author(s):  
Hege O. Ohnstad ◽  
Øyvind S. Bruland ◽  
Ingeborg Taksdal ◽  
Bodil Bjerkehagen ◽  
Maja Nenadovic ◽  
...  

2020 ◽  
Vol 37 (4) ◽  
pp. 509-517
Author(s):  
Teruya Kawamoto ◽  
Hitomi Hara ◽  
Masayuki Morishita ◽  
Naomasa Fukase ◽  
Yohei Kawakami ◽  
...  

2006 ◽  
Vol 2 (4) ◽  
pp. 135-138 ◽  
Author(s):  
Manabu Hashimoto ◽  
Etuko Tate ◽  
Jiro Watarai ◽  
Masahiro Sasaki

2021 ◽  
Vol 1 (2) ◽  
pp. 89-94
Author(s):  
MASATAKE MATSUOKA ◽  
MASANORI OKAMOTO ◽  
TAMOTSU SOMA ◽  
ISAO YOKOTA ◽  
RYUTA ARAI ◽  
...  

Background/Aim: Although smoking history is predictive of poor pulmonary metastasis-free survival (PMFS) in patients with epithelial tumors, the impact of smoking history on PMFS in those with soft-tissue sarcoma (STS) is not known. Patients and Methods: Patients undergoing treatment for STS at our institutes between 2008 and 2017 were enrolled. Patients were excluded if they had metastatic lesion, or had a histopathological classification demonstrating small round-cell sarcoma. The impact of smoking history on PMFS and overall survival was examined with multivariate analysis using a Cox proportional hazards model. Results: A total of 250 patients were retrospectively reviewed. Patients with smoking history had worse PMFS on multivariate analysis (hazard ratio=2.00, 95% confidence interval=1.12-3.60). On the other hand, smoking history did not significantly affect overall survival (hazard ratio=1.26, 95% confidence interval=0.61-2.58). Conclusion: Patients with STS need to be followed-up by frequent clinical assessments if they have a smoking history.


2020 ◽  
Vol 13 (2) ◽  
pp. 191-194
Author(s):  
Taynah Puty ◽  
Tiago França ◽  
Paula Oliveira ◽  
Luís Eduardo Carvalho ◽  
Nise Yamaguchi

2020 ◽  
Vol 18 (1) ◽  
Author(s):  
Qiang Wu ◽  
Zengwu Shao ◽  
Yubin Li ◽  
Saroj Rai ◽  
Min Cui ◽  
...  

Abstract Background Closure of large skin-soft tissue defects following soft tissue sarcoma (STS) resection has been a great challenge. The objective of this study was to evaluate the effectiveness of a novel, simple, and cheap skin-stretching device (bidirectional regulation-hook skin closure system, BHS) for closing large skin-soft tissue defects resulting from the removal of STS and the complications associated with the use of the BHS. Methods From January 2017 to September 2018, 25 patients with STS underwent BHS therapy after tumor resection. BHS was used for two main clinical applications: securing wound closure after high-tension suture closure and delayed wound closure. We described a detailed reconstruction procedure regarding this therapy. Wound closure and complications associated with BHS therapy were recorded. We also analyzed tumor recurrence and metastases. Results All patients were observed for 16–36 months with an average follow-up of 25.6 months. During the follow-up period, no significant functional restriction was observed and the final scar was aesthetically acceptable. Superficial wound infection occurred in six patients, wound edge ischemia in two patients, and small skin tears in two patients. Two patients developed pulmonary metastasis, two patients had a local recurrence, and one patient died of pulmonary metastasis. Conclusions BHS therapy can effectively close large skin-soft tissue defects following STS resection and obtain acceptable functional results, without severe complications. However, larger studies are required to further evaluate the effectiveness, indications, and complications of BHS therapy.


Sign in / Sign up

Export Citation Format

Share Document